Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
27
10
2022
accepted:
27
03
2023
medline:
27
9
2023
pubmed:
26
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Excessive deposition and crosslinking of extracellular matrix increases liver density and stiffness, promotes fibrogenesis, and increases resistance to fibrinolysis. An emerging therapeutic opportunity in liver fibrosis is to target the composition of the extracellular matrix or block pathogenic communication with surrounding cells. However, the type and extent of extracellular changes triggering liver fibrosis depend on the underlying etiology. Our aim was to unveil matrisome genes not dependent on etiology, which are clinically relevant to liver fibrosis. We used transcriptomic profiles from liver fibrosis cases of different etiologies to identify and validate liver fibrosis-specific matrisome genes (LFMGs) and their clinical and biological relevance. Dysregulation patterns and cellular landscapes of LFMGs were further explored in mouse models of liver fibrosis progression and regression by bulk and single-cell RNA sequencing. We identified 35 LFMGs, independent of etiology, representing an LFMG signature defining liver fibrosis. Expression of the LFMG signature depended on histological severity and was reduced in regressive livers. Patients with liver fibrosis, even with identical pathological scores, could be subclassified into LFMG Low and LFMG High , with distinguishable clinical, cellular, and molecular features. Single-cell RNA sequencing revealed that microfibrillar-associated protein 4 + activated HSC increased in LFMG High patients and were primarily responsible for the LFMG signature expression and dysregulation. The microfibrillar-associated protein 4 + -activated HSC-derived LFMG signature classifies patients with liver fibrosis with distinct clinical and biological characteristics. Our findings unveil hidden information from liver biopsies undetectable using traditional histologic assessments.
Sections du résumé
BACKGROUND AIMS
Excessive deposition and crosslinking of extracellular matrix increases liver density and stiffness, promotes fibrogenesis, and increases resistance to fibrinolysis. An emerging therapeutic opportunity in liver fibrosis is to target the composition of the extracellular matrix or block pathogenic communication with surrounding cells. However, the type and extent of extracellular changes triggering liver fibrosis depend on the underlying etiology. Our aim was to unveil matrisome genes not dependent on etiology, which are clinically relevant to liver fibrosis.
APPROACH RESULTS
We used transcriptomic profiles from liver fibrosis cases of different etiologies to identify and validate liver fibrosis-specific matrisome genes (LFMGs) and their clinical and biological relevance. Dysregulation patterns and cellular landscapes of LFMGs were further explored in mouse models of liver fibrosis progression and regression by bulk and single-cell RNA sequencing. We identified 35 LFMGs, independent of etiology, representing an LFMG signature defining liver fibrosis. Expression of the LFMG signature depended on histological severity and was reduced in regressive livers. Patients with liver fibrosis, even with identical pathological scores, could be subclassified into LFMG Low and LFMG High , with distinguishable clinical, cellular, and molecular features. Single-cell RNA sequencing revealed that microfibrillar-associated protein 4 + activated HSC increased in LFMG High patients and were primarily responsible for the LFMG signature expression and dysregulation.
CONCLUSIONS
The microfibrillar-associated protein 4 + -activated HSC-derived LFMG signature classifies patients with liver fibrosis with distinct clinical and biological characteristics. Our findings unveil hidden information from liver biopsies undetectable using traditional histologic assessments.
Identifiants
pubmed: 37098756
doi: 10.1097/HEP.0000000000000423
pii: 01515467-990000000-00407
pmc: PMC10524702
mid: NIHMS1903372
doi:
Substances chimiques
Extracellular Matrix Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1118-1132Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK111677
Pays : United States
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Hepatology. 2017 May;65(5):1432-1434
pubmed: 28195336
Biomed Res Int. 2016;2016:3162670
pubmed: 27843941
Hepatology. 2020 Feb;71(2):749-751
pubmed: 31483871
J Cell Physiol. 2019 Dec;234(12):22613-22622
pubmed: 31102291
Crit Care. 2011;15(6):R266
pubmed: 22082207
Gut. 2017 Sep;66(9):1697-1708
pubmed: 28073888
JHEP Rep. 2020 Apr 18;2(4):100115
pubmed: 32637906
J Clin Invest. 2019 Jul 11;129(10):4091-4109
pubmed: 31295147
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-84.e1-2; quiz e88-9
pubmed: 23954643
Hepatol Commun. 2021 Sep;5(9):1571-1585
pubmed: 34510837
Nucleic Acids Res. 2022 Jan 7;50(D1):D27-D38
pubmed: 34718731
Hepat Oncol. 2018 Sep 11;5(1):HEP10
pubmed: 30302198
J Transl Med. 2016 Jul 04;14(1):201
pubmed: 27378383
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5
pubmed: 25865049
J Hepatol. 2014 Aug;61(2):260-269
pubmed: 24583249
Nature. 2019 Nov;575(7783):512-518
pubmed: 31597160
Lancet. 2013 Feb 9;381(9865):468-75
pubmed: 23234725
Cell Rep. 2019 Nov 12;29(7):1832-1847.e8
pubmed: 31722201
Clin Mol Hepatol. 2019 Mar;25(1):42-51
pubmed: 30449076
Liver Int. 2020 Jul;40(7):1701-1712
pubmed: 32339377
Front Pharmacol. 2021 May 06;12:671640
pubmed: 34025430
Front Bioeng Biotechnol. 2022 Feb 16;10:821852
pubmed: 35252131
Liver Int. 2015 Jan;35 Suppl 1:78-81
pubmed: 25529091
Hepatol Commun. 2018 Feb 13;2(4):467-476
pubmed: 29619424
Cancers (Basel). 2021 May 09;13(9):
pubmed: 34065048
Adv Drug Deliv Rev. 2017 Nov 1;121:43-56
pubmed: 28736303
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Matrix Biol. 2018 Aug;68-69:435-451
pubmed: 29656147
J Clin Invest. 2018 Jan 2;128(1):74-84
pubmed: 29293092
JHEP Rep. 2020 Jan 20;2(2):100067
pubmed: 32118201
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L344-57
pubmed: 25502501
Hepatology. 2017 May;65(5):1438-1450
pubmed: 28027574
Matrix Biol. 2016 Jan;49:10-24
pubmed: 26163349
Int J Mol Sci. 2021 Nov 26;22(23):
pubmed: 34884600
J Proteomics. 2010 Jun 16;73(8):1421-32
pubmed: 20026004
Nat Commun. 2021 Jun 18;12(1):3785
pubmed: 34145257
Trends Cell Biol. 2022 Jan;32(1):70-90
pubmed: 34810063
Front Pharmacol. 2022 Feb 11;13:787748
pubmed: 35222022
Am J Pathol. 2014 Feb;184(2):309-21
pubmed: 24139945
Nat Cancer. 2022 Apr;3(4):505-517
pubmed: 35469013
Hepatology. 2020 Aug;72(2):729-741
pubmed: 32176358
Hepatol Int. 2020 Jul;14(4):463-474
pubmed: 32578019
Matrix Biol. 2022 Aug;111:1-25
pubmed: 35644509